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Abstract. Human malignant melanoma is notoriously 
resistant to pharmacological modulation. We describe 
here for the first time that the synthetic retinoid CD437 
has a strong dose-dependent antiproliferative effect on 
human melanoma cells (IC50:5 ×  10-6 M) via the in- 
duction of programmed cell death, as judged by analy- 
sis of cell morphology, electron microscopical features, 
and DNA fragmentation. Programmed cell death was 
preceded by a strong activation of the AP-1 complex in 
CD437-treated cells as demonstrated by gel retardation 
and chloramphenicol transferase (CAT) assays. North- 
ern blot analysis showed a time-dependent increase in 
the expression of c-los and c-jun encoding components 
of AP-1, whereas bcl-2 and p53 mRNA levels remained 
constant. CD437 also exhibited a strong growth inhibi- 
tory effect on MeWo melanoma cells in a xenograft 
model. In tissue sections of CD437-treated MeWo tu- 
mors from these animals, apoptotic melanoma cells and 
c-los overexpressing cells were colocalized by TdT- 
mediated deoxyuridine triphosphate-digoxigenin nick 
end labeling (TUNEL) staining and in situ hybridiza- 
tion. Taken together, this report identifies CD437 as a 
retinoid that activates and upregulates the transcription 
factor AP-1, leading eventually to programmed cell 
death of exposed human melanoma cells in vitro and in 
vivo. Further studies are needed to evaluate whether 
synthetic retinoids such as CD437 represent a new class 
of retinoids, which may open up new ways to a more ef- 
fective therapy of malignant melanoma. 
"r~ETINOIOS, structural analogs of vitamin A, are in- 
~-~  volved in a wide range of biologicaI processes  in- 
.It. ~  cluding  cell  differentiation, morphogenesis,  and 
proliferation (for reviews  see  Kastner et al.,  1995; Man- 
gelsdorf and Evans, 1995). These parameters have been 
analyzed in various murine and human cancer cell lines in- 
cluding  melanoma for more  than  fifteen years  (Lotan, 
1980; Meyskens and Fuller, 1980; Hoal et al., 1982). Al- 
though their clinical usefulness has so far been limited by 
various adverse effects, retinoids are of increasing impor- 
tance  for the  development of oncological  strategies  be- 
cause of their antineoplastic activity (for reviews see Bollag 
and Holdener, 1992; Smith et al., 1992; Kurie et al., 1994). 
These may be mediated either directly by toxic membrane 
damage or by activation of oxidative  processes  or indi- 
rectly by induction of tumor suppressive  mediators or by 
modulation of receptors necessary for growth factor inter- 
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action or immune recognition (Evans, 1988; Apfel et al., 
I991;  Mangelsdorf and Evans,  1995). At  the  molecular 
level it is known that retinoids bind to and activate specific 
nuclear receptors, the retinoic acid receptors (RARs)  1  and 
retinoid X receptors (RXRs), which in turn, as homo- or 
heterodimers, recognize  specific DNA sequences  regulat- 
ing target gene expression  (for reviews  see Apfel et al., 
1991; Kastner et al., 1995; Mangelsdorf and Evans,  1995). 
Recently, it has been shown that retinoids interfere with 
other  transcription  factors,  particularly AP-1,  which  is 
formed by members of the Fos  and Jun protein family 
(Schtile et al.,  1990, 1991; Yang-Yen  et al.,  1991; Pfahl, 
1993). AP-1 inhibition leads to antiproliferative effects in 
tumor cells  independent of the  receptor-transactivating 
potential of the retinoids (Fanjul et al., 1994; J.-Y. Chen et al., 
1995; Li et al., 1996). 
1. Abbreviations used in this paper: ATF, activating transcription factor; 
CAT,  chloramphenicol transferase; CREB,  cAMP-responsive element- 
binding protein; RA, all-trans-retinoic acid; RAR and RXR, retinoic acid 
and retinoid X receptors; TUNEL, TdT-mediated deoxyuridine triphos- 
phate-digoxigenin nick end labeling. 
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fully for the treatment of malignant  melanoma  (Ho and 
Sober, 1990; Lotan et al., 1991). Only recently, a RAR-~t- 
selective  synthetic  retinoid  CD437  has  been  identified 
(Bernard et al., 1992) that strongly inhibited in vitro cell 
proliferation of various human  melanoma cell lines in a 
close-dependent manner (Schadendorf et al., 1994). Since 
malignant melanoma cells are notoriously resistant to che- 
motherapeutic drugs in vitro and in vivo (Ho and Sober, 
1990; Schadendorf et al.,  1995) and new strategies for the 
treatment  of metastatic  melanoma are  urgently needed, 
we used the human melanoma cell line MeWo as a model 
system for studying the  mechanism  involved in  CD437- 
induced  growth  inhibition  in  greater  detail.  CD437  is 
shown to be capable of inducing the transcription factor 
AP-1 on mRNA and protein levels leading eventually to 
programmed cell death of MeWo ceils in vitro. Further- 
more, treatment with CD437 markedly reduced the growth 
of human melanoma cells in nude mice. 
Materials and Methods 
Cell Culture andExposure to Retinoids 
Human melanoma cells (MeWo, SK-Mel-23, and MV-3) were grown in 
RPMI 1640 medium (GIBCO BRL, Eggenstein, Germany) supplemented 
with charcoal-treated 10%  FCS (Schadendorf et al.,  1993). For retinoid 
treatment, the same medium was used. The medium and retinoids were 
changed every 3 d. The retinoids all-trans-retinoic acid (RA), CD437, and 
CD2398 were used. CD437 is known to activate RAR-'¢ with high selectiv- 
ity, whereas CD2398,  which is structurally highly homologous to CD437, 
has no binding affinity to any known retinoid receptor. RA binds to all 
RAR subtypes with high affinity hut not to RXR receptors (Bernard et 
al., 1992; Schadendorf et al., 1994). All retinoids were kindly provided by 
Drs. B. Shroot and U. Reichert (CIRD, Galderma, Valbonne, France) 
and were dissolved in DMSO. The final concentration in all cultures was 
0.1% DMSO. 
Electrophoretic Mobility Shift Assay 
5 × 106 cells were stimulated with RA, CD437, and CD2398 (10 -5 M) for the 
times  indicated.  Cell  extracts  were  prepared  as  described previously 
(Trede et al., 1991; Pahl and Baeuerle, 1995). Total cell extracts were pre- 
pared using high-salt detergent buffer (Totex; 20 mM Hepes, pH 7.9, 
350 mM NaCl, 20% [wt/vol} glycerol, 1% [wt/vol] NP-40, 5 mM MgClz, 
0.5 mM EDTA, 0.1 mM EGTA, 0.5 mM DTr, 0.1% PMSF, and 1% apro- 
tinin). Cells were harvested by centrifugation and washed once in ice-cold 
PBS and resuspended in 4 vol of Totex buffer. The cell lysate was incu- 
bated on ice for 30 rain and then centrifuged for 5 rain at 13,000 g at 4°C. 
The  protein  content  of  the  supernatant  was  determined,  and  equal 
amounts of protein (10-20 p~g) were added to a reaction mixture contain- 
ing 20 ~g BSA (Sigma Chemical Co., St. Louis, MO), 2 p,g poly(di-dC) 
(dldC purchased from Pharmacia LKB Biotechnology, Piscataway, NJ), 
2 ~I buffer D+ (20 mM Hepes, pH 7.9, 20% glycerine, 100 mM KCI, 0.5 mM 
EDTA, 0.25% NP-40, 2 mM DTT, 0.1% PMSF), 4 In,1  buffer F (20% Ficoll 
400,  100  mM  Hepes, 300  mM KCL,  10  mM DTT,  0.1%  PMSF), and 
100,000 cpm of et-32p-labeled  oligonucleotide in a final volume of 20 I~l- 
Samples were incubated at room temperature for 25 rain.  For the super- 
shift assays, 2.5 ILl of antibody were added to the reaction simultaneously 
with the protein and incubated as described. The following antibodies 
were all purchased from Santa Cruz Biotechnology (Santa Cruz, CA): 
4-10G (mouse IgG2~; broadly reactive with c-Fos, Fos B, Fra-1, and Fra-2), 
4 (rabbit polyclonal IgG; reactive with c-Fos), 102 (rabbit polyclonal IgG; 
reactive with Fos B), R-20 (rabbit polyclonal IgG; reactive with Fra-1), 
Q-20 (rabbit polyclonal IgG; reactive with Fra-2), N  (rabbit polyclonal 
IgG; reactive with c-Jun), N-17 (rabbit polyclonal IgG; reactive with Jun B), 
329 (rabbit polyclonal IgG; reactive with Jun D), C-21 (rabbit polyclonal 
IgG; reactive with cAMP-responsive element-binding protein 1 [CREB- 
1]);  C-20 (rabbit polyclonal IgG; reactive with CREB-2 and  activating 
transcription factor 4 [ATF-4]), FI-I (rabbit polyclonal IgG; reactive with 
ATF-1), C-19 (rabbit polyclonal IgG; reactive with ATF-2), C-19 (rabbit 
polyclonal IgG; reactive with ATF-3), and Z5 (mouse monoclonal IgG~; 
reactive with ATF-4).  AP-1  oligonucleotide (Promega Corp., Madison, 
WI) was labeled using [3,-32p]ATP (3,000 Ci/ml; Amersham Corp., Arling- 
ton Heights, IL) and T4 polynucleotide kinase (Promega Corp.). 
DNA Transfection and CAT Assay 
Cells were DNA transfected using cationic liposomes (Lipofectin; Life 
Technology, Inc., Eggenstein, FRG) under serum-free conditions as de- 
scribed previously (Artuc et al.,  1995).  For the transfection assay, ceils 
were seeded into 6-well plates at a density of 12,000 cells/era  2. Cultures 
were transfected 1 d after they reached 50--60% confluency, and cells were 
incubated with DNA-liposome complexes (2 p,g DNA per well) for 24 h. 
To exclude differences in transfection efficiency, cotransfection of a cy- 
tomegalovirus-driven [3-galactosidase  construct (Stratagene, Heidelberg, 
Germany) was performed in each experiment (1 p,g per well). 48 h after 
transfection, cells were washed twice with PBS and harvested. After cen- 
trifugation, the pellet was resuspended in 0.125 M Tris HC1 buffer, pH 7.8, 
and lysed by repeated cycles of freezing and thawing at -80°C, and the to- 
tal protein concentration of the cell lysates was determined. To determine 
AP-l-dependent CAT activities, a DNA fragment containing five AP-1 
DNA-binding sites was generated by PCR (primer: ACTgAATCAAC- 
TgAATCAACTgAATCAACTgAATCAACTgAATCATT)  cloned into 
the BgllI site of the pCAT-promoter vector (Promega Corp.), and the re- 
sulting plasmid was transfected into MeWo cells. CAT activity was mea- 
sured as described previously (Artuc et al., 1995; Ntirnberg et al., 1995). 
Commercially available CAT was used as a standard for the determina- 
tion of enzyme activity in extracts of transfected cells. Transfection effi- 
ciency was estimated by cotransfection of a  !3-galactosidase  plasmid in 
each experiment. 
Northern Blot Analysis and In Situ Hybridization 
RNA was isolated using an RNeasy Total RNA Kit (QIAGEN Inc., Chats- 
worth, CA), electrophoresed through 1% agarose-formaldehyde gels, and 
then  transferred  to  nylon  membranes  (Boehringer Mannheim Corp.). 
Northern blot  hybridization to  random-primed 32p-labeled  DNAs  and 
high stringency washes were performed as described (Sambrook et al., 
1989). Signals were visualized by autoradiography. The eDNA probes for 
c-los, c-jun (Ntirnberg et al., 1995), and p53 (Baker et al., 1990) were ex- 
cised from their plasmid vectors and random-primed with [ot-32P]dCTP 
(3,000 Ci/mmol; Du Pont-New England Nuclear, Boston, MA). For in situ 
hybridization, digoxigenin-labeled antisense and sense c-los riboprobes 
were synthezised using T7 and SP6 RNA polymerase (DIG-RNA labeling 
kit; Boehringer Mannheim Corp.). The hybridization procedure of paraf- 
fin-embedded sections of cutaneous tumors followed a standard protocol 
using a colorimetric detection system (Ntirnberg et al., 1995). 
Electron Microscopy 
The  method used has  been  described in  detail  elsewhere (Kolde and 
Knop, 1986). Briefly, the cells were fixed in half-strength Karnovsky sola- 
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Figure  1.  Structural  for- 
mula.  Structures of (RA), 6- 
[3-adamantyl-4-hydroxyphe- 
nyl]-2-naphtalene  carboxylic 
acid  (CD437),  and  6-[3-ada- 
mantyl-4-hydroxyphenyl]-2- 
naphtalene  aldehyde  (CD- 
2398). 
The Journal of Cell Biology, Volume 135, 1996  1890 tion (0.1 M cacodylate buffer, pH 7.4) for 30 min at 4°C. After washing in 
PBS,  the cells were postfixed in  1.33%  osmic acid  (0.05  M  phosphate 
buffer, pH 7.4) for 30 min, dehydrated in a graded ethanol series, and em- 
bedded in Araldite using beam capsules. Ultrathin sections were stained 
with uranyl acetate and lead citrate and examined with an electron micro- 
scope (model 9S; Carl Zeiss, Inc., Thornwood, NY). Necrotic and apop- 
totic cell figures were counted and expressed by a semiquantitative scor- 
ing system as follows: 0, no cell with altered morphology; +/- single cells 
(up to 3%); +, few cells (between 3-10%); + +, moderate number of cells 
(11-50%); + + +, numerous cells (>50%). 
Melanoma Nude Mouse Model 
For the in vivo experiments, male Swiss-nu/nu mice (Bomholtgaard; Ry, 
Denmark) weighing 20-25 g were used. Mice were kept under sterile con- 
ditions at 24-26°C room temperature, 50%  relative humidity, and  12 h 
light-dark rhythm in laminar flow shelves and were supplied with auto- 
claved food (Sniff; Soest, Germany) and bedding. The drinking water was 
filtered and acidified (pH 4.0).  For treatment of melanoma xenografts, 
previously established MeWo melanoma tumors of 1-2 mm in diameter 
were implanted into the right flank of animals. After tumor growth for 10 d, 
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Figure 2.  Growth inhibitory effects of retinoids on melanoma cells in vitro. Human  melanoma cells (MeWo, MV3, SK-Mel-23) were 
grown to ~70% confluency, and at time zero, retinoids were added. (A) CD437 was added over a concentration range from 10  -s to 10 -5 M, 
and viable cells were counted after 72 h. (B) MeWo cells were cultured in the presence of retinoids (10 -8 to 10 -5 M), and viable cells 
were counted after 48 h. (C) MeWo cells were cultured in the presence of retinoids (10  -s M  each), and viable cells were counted at the 
times indicated. (D) MeWo cells were treated with CD437 (5 ×  10 -6 M) for the times indicated. After removal of CD437, cells were al- 
lowed to recover in retinoid-free medium for 72 h. As vehicle control, DMSO (0.1%) was used in all experiments. Results are expressed 
as means -+ SEM (n =  5). 
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Figure 3.  Analysis of DNA fragmentation of human melanoma 
cells upon treatment with retinoids  in vitro.  MeWo melanoma 
cells were treated with CD437, CD2398, and RA over a concen- 
tration range from 10 -8 to 10 -5 M for 48 h, and control cultures 
were incubated with DMSO (0.1%)  as vehicle control.  Historic- 
associated  DNA fragments released from the cytoplasmic  frac- 
tions of retinoid-treated cells were quantified  using a Cell Death 
Detection ELISA (Boehringer Mannheim Corp.)  according  to 
the manufacturer's instructions. Data are given as means _+ SEM 
(n  =  5). 
groups of mice (n = 8) were either treated with saline p.o. or were injected 
intratumorally for 3 wk or were fed with various concentrations  of CD437 
(10 mg/kg/body weight and 30 mg/kg/body weight). In addition, tumors of a 
fifth  group were injected  with CD437  (10 mg/kg/body weight) each day. 
Mice were visited  daily and growing tumors were measured twice weekly 
with a caliperlike  instrument. No signs of major toxicity were observed, as 
judged by loss of body weight over the treatment period. CD437-treated 
animals showed, however, some scaling  of the skin,  which is typical  for 
retinoid treatment. 
Results 
CD437 Induces Programmed Cell Death In Vitro 
CD437  is  a  new  aromatic retinoid  that  causes  selective 
RAR-~/activation (Bernard et aI., 1992) and that has re- 
cently been shown  to induce  apoptosis in  human breast 
cancer cells (Shao et al., t995).  We tested CD437  for its 
antiproliferative effects on different human melanoma cell 
lines (MeWo, MV3, and SK-Mel-23) in comparison to the 
structurally closely related compound CD2398, which does 
not bind to any known retinoid receptor (Bernard et al., 
1992;  Schadendorf et al.,  1994),  and  RA (Fig.  1).  Treat- 
ment for 72 h with CD437 caused a strong dose-dependent 
growth inhibition in all melanoma cell lines (Fig. 2 A). At a 
concentration of 5 ×  10  -6 M  CD437, only about 5-25% of 
the cells remained viable after 3 d. The concentrations of 
CD437 required for 50% growth inhibition  (I(250) ranged 
from  10 -6 M for MeWo to 10 -7 M for SK-Mel-23 showing 
the highest sensitivity. In contrast, proliferation of all cell 
lines was not affected in the presence of RA (10-s-10 -s 
M)  (data  not shown).  Using MeWo  melanoma cells,  we 
studied the effect of retinoids in more detail.  In Fig. 2 B, 
the  effect of  CD437,  RA,  and  CD2398  on MeWo  cell 
growth  is  shown.  CD437  in  the  range  of  10-6-t0 -5  M 
strongly inhibited cell growth. In contrast, CD2398 had a 
moderate inhibitory effect only at the highest concentra- 
tion  tested  (10 -5  M),  and  RA-treated  cultures  retained 
normal ceil  growth.  As  shown  in  Fig.  2  C,  the  CD437- 
induced  growth inhibition  is time dependent;  again,  RA 
did  not  affect  cell  proliferation,  and  treatment  with 
CD2398  (10 -5 M) resulted  in  an ~30%  reduction  in the 
number of viable ceils after prolonged exposure (72 h). At 
present, the mechanism of the reduced growth inhibitory 
effect of CD2398 is completely unknown and might be due 
to  interaction  of  the  hydrophobic  retinoid  with  mem- 
branes or, since  CD2398  does not bind  to receptors  of 
the RAR and RXR family (Bernard et al.,  1992),  activa- 
tion of a yet unknown receptor. To test whether the effect 
of CD437  is reversible or irreversible, MeWo cells were 
treated with CD437 for different time periods (6,  12, 24, 
36,  and 48 h) followed by a 72-h regeneration period. As 
outlined  in Fig. 2 D, the antiproliferative effect could be 
partially reversed after short-time exposure to CD437 for 
6 or 12 h, respectively, with a recovery of around 45-55% 
of viable cells after the regeneration period compared to 
controls. In contrast, prolonged CD437 exposure (24--48 h) 
resulted  in  an  irreversible  growth  inhibition  (Fig.  2  D). 
Furthermore, MeWo cells were sensitive to phorbol ester- 
induced growth inhibition up to 40%  at PMA concentra- 
tions  ranging  from  10--100  ng/ml  (data  not  shown).  The 
same results were obtained with MV3 cells, whereas SK- 
Mel-23 cells did not respond to PMA treatment under the 
conditions tested (data not shown). 
In comparison to untreated cells, the cell morphology of 
CD437-treated MeWo cells was changed dramatically (not 
shown), suggesting the possible induction of programmed 
cell death. To test this hypothesis, histone-associated DNA 
fragments (nucleosomes) in the cytoplasmatic fraction of 
MeWo cells treated with the three compounds over a con- 
centration range from 10 -8 M  to 10 .5 M  were quantified 
by a cell death detection ELISA. As shown in Fig. 3, RA 
had no effect and CD2398 caused a 5-7-fold increase of his- 
tone-associated DNA fragments only at the highest con- 
centrations tested (10 -s M). A  dramatic increase in DNA 
fragmentation  (6-12-fold)  could  be  observed in  CD437- 
treated cells over a  concentration range from 10 .6 M  to 
10 -5 M. In agreement with these findings, electron micros- 
copy revealed regularly structured cells in untreated (Fig. 
4 A) or RA-treated preparations, whereas various amounts 
of apoptotic and necrotic melanoma cells were detectable 
in CD437-treated groups (Fig. 4, B and C). After adminis- 
tration of compound CD437, there were numerous apop- 
totic melanoma cells and  a  few cells with necrotic alter- 
ations, while in  the controls, no necrotic and only few if 
any  apoptotic  cells  were  found.  Apoptotic  MeWo  cells 
were characterized by segregation of compacted chroma- 
tin,  condensation  of  cytoplasm  and  organelles,  intact 
membranes, and fragmentation of the cell (Fig. 4  B).  In 
contrast, the rare necrotic cells demonstrated swelling of 
the cytoplasm and  mitochondria,  edematous  nuclei  with 
clumped chromatin, and dissolution of membranes (Fig. 4 
C). The relative numbers of apoptotic and necrotic mela- 
noma cells were assessed by a semiquantitative ultrastruc- 
tural analysis, as summarized in Table I. Whereas necrotic 
The Journal of Cell Biology, Volume 135, 1996  1892 Figure 4.  Electron micrographs of untreated and CD437-treated  MeWo melanoma cells. (A) Regularly structured melanoma cell in 
DMSO-treated control preparation (4700×).  (B) Apoptotic melanoma cell with condensed  and fragmented nucleus  and cytoplasmic 
blebbing after treatment with CD437 (5  x  10  -6 M; 72 h) (6100x). (C) Necrotic melanoma cell with toxic alterations  such as swelling 
and dissolution of the nucleus and cytoplasm (5200×).  Bars: (A and C) 3 ~m; (B) 2 ~tm. 
cells were not detectable in control cells or cells exposed 
to CD2398 or RA, CD437-treated cells exhibited few cells 
(up to 10%); however, cells were found to undergo apop- 
totic death in more than 75%  upon exposure. Apoptotic 
ceils were also found in up to 10% of the cells treated with 
RA or CD2398. 
Activation of  AP-1 upon Treatment with CD437 
In Vitro 
Since  antiproliferative  effects of synthetic retinoids  have 
recently been attributed to an anti-AP-1  activity (Fanjul 
et al., 1994; J.-Y. Chen et al., 1995; Li et al., 1996), we stud- 
ied the effects of CD437 on AP-1 activation. Using a vec- 
tor  containing  five  repeated  AP-1  DNA-binding  sites 
cloned in front of the CAT-reporter gene, we observed a 
20-fold CAT induction  after treatment with CD437  (5  x 
Table L Semiquantitative  Ultrastructural Evaluation of 
Apoptotic and Necrotic MeWo Melanoma Cells Treated with 
either CD437,  CD2398,  or RA (5 X  10 -6 M)  for 72 h, 
Compared to DMSO (0.1%) Treatment and Untreated Me  Wo 
Cells (control). 
Incubation  Apoptosis  Necrosis 
Control  +/-  O 
DMSO  +/-  Q 
CD437  +  +  +  + 
CD2398  + 
RA  + 
O, no cell with altered morphology. 
+/-,  single cells. 
+, few cells. 
+ +, moderate number of cells. 
+ + +, numerous cells. 
10  -6 M, 72 h) (Fig. 5). In contrast, MeWo cells treated with 
CD2398  or RA showed no  increase  in  AP-l-dependent 
CAT activity. Cotransfection of a full-length c-fos expres- 
sion plasmid led to a 2.5-fold CAT induction (Fig. 5), simi- 
larly to treatment of MeWo cells with PMA (100 ng/ml), a 
well-known activator of AP-1. The latter is in agreement 
with the observed moderate effect of PMA on growth of 
MeWo cells. 
Furthermore, electrophoretic mobility shift assays using 
an oligonucleotide containing an AP-1 DNA-binding mo- 
tif as a probe confirmed upregulation of the AP-1 complex 
after exposure to CD437 (Fig. 6 A). This protein-DNA in- 
teraction  was  specifically competed  for  by  an  excess  of 
cold probe. In contrast, no such dramatic changes were ob- 
served in the presence of CD2398 and RA (5  x  10 -5 M, 
each)  (Fig. 6 A). Nuclear extracts of MeWo cells treated 
with these  compounds showed only weak binding of the 
AP-1  sites.  Since DNA binding  of other unrelated  tran- 
scription  factors  such  as  Nil-2  (not  expressed)  or  Oct-1 
(highly expressed) was not changed by the retinoid treat- 
ment (Fig. 6 B), it can be assumed that CD437 specifically 
activates DNA binding of the AP-1 complex. AP-1 activa- 
tion became visible as early as 3 h after exposure to CD437 
and remained high for up to 48 h  (Fig. 6 C). Cells treated 
with RA or CD2398 also showed a slight increase in AP-1 
DNA-binding  activity  (Fig.  6  C);  however,  AP-1  com- 
plexes built upon RA or CD2398 treatment were not tran- 
scriptionally active as suggested by the  activation  of the 
CAT gene (Fig. 5) and the lack of growth inhibition (Fig. 2). 
The AP-1 complex upon treatment with CD437 is formed 
by multiple members of the  Fos  and  Jun  protein  family 
(Fig. 6 D). Dissection of the AP-1 complex by gel retarda- 
tion  assays using nuclear extracts of melanoma cells and 
monospecific antibodies in a supershift assay revealed that 
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Figure 5.  AP-l-dependent CAT expression is increased by treat- 
ment  with  CD437.  Retinoid  treatment  (RA,  CD437, and 
CD2398) at a concentration of 5 ×  10  6 M was started 24 h before 
transfection. For control, a  full-length c-fos expression plasmid 
was cotransfected in a fourth set of experiments. CAT activities 
(13-galactosidase corrected) shown as bars were calculated as rela- 
tive activities by arbitrarily setting the activity of untreated but 
control-transfected cells at 1. Results are expressed as means - 
SEM (n =  4). 
c-Fos and the Jun family members c-Jun and JunD  are in- 
volved in AP-1 complex formation in CD437-treated cells 
(Fig. 6  D, upper).  In contrast with cell extracts prepared 
from  RA-treated cells, weak  signals were  obtained  after 
coincubation  with  antibodies  against  Fra-1,  c-Jun,  and 
JunD  (Fig. 6 D, lower). Under both conditions, ATF and 
CREB proteins do not participate in the AP-1 complex. 
Northern  blot  analysis confirmed  that  mRNA  expres- 
sion  of  the  protooncogenes  c-los  and  c-jun,  encoding 
members of the AP-1 complex, was concurrently upregu- 
lated  after  a  48-  to  72-h  exposure  to  CD437  (Fig.  7), 
whereas CD2398  and RA had no such effect. Expression 
of p53 (Fig. 7), which encodes a negative growth regulator 
and  expression  of  the  antiapoptotic  gene  bcl-2  (not 
shown),  was  not  altered in  MeWo  cells upon  treatment 
with any of the compounds  (Fig. 7).  Taken  together,  gel 
shift assays demonstrated a CD437-induced increased AP-1 
DNA-binding activity already 3 h  after exposure to the ret- 
inoid (Fig. 6), suggesting that posttranslational activation 
of  the  transcription  factor  is  a  primary  event  during 
CD437-induced  apoptosis.  As  shown  by  Northern  blot 
analysis (Fig. 7), prolonged exposure to CD437 also stimu- 
lates expression of genes encoding components of the AP-1 
complex. 
Growth Inhibition of Human Melanoma Xenograft in 
Nude Mice with CD437 Treatment 
To confirm the significance of the results obtained in vitro 
Figure 6.  Treatment of MeWo melanoma cells with CD437 up- 
regulates the  AP-1 complex. Total cell extracts prepared from 
unstimulated  (control,  C)  or  retinoid-stimulated  cells  (RA, 
CD437, and CD2398; 10 -5 M, 24  h) were subjected to electro- 
phoretic mobility shift assays. In A, extracts were incubated with 
a 32p-labeled AP-1 DNA-binding sequence in the absence (-) or 
presence (+)  of unlabeled competitor (100-fold molar excess), 
and  in  B,  oligonucleotides containing either  an  Oct-l-binding 
motif (CGA ATG CAA ATC ACT AGA) or a Nil-2 DNA-bind- 
ing sequence (CAG ACA GGT AAA GAT CAG ACA GGT 
AAA GA) were used. (C) After addition of retinoids (5 ×  10 -5 M 
each), cell extracts were prepared at the times indicated, incu- 
bated with an oligomer containing an AP-1 DNA-binding site, 
and analyzed in comparison to the untreated control (C). (D) Su- 
pershift mobility assays of MeWo cells treated with CD437 (3 h, 
5 X  10 -6 M, upper) or RA (48 h, 5 ×  10 -6 M, lower). Cell extracts 
and antibodies monospecific for various possible components of 
the AP-1 complex (Fos and Jun proteins, ATF, CREB) were co- 
incubated as described in Materials and Methods. The original 
data were digitally  processed using a Hewlett-Packard Scan Jet IIcx. 
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cells express  c-los  and c-jun 
after CD437 treatment. RNA 
was isolated  from cultures  at 
intervals  as  indicated  after 
exposure to RA, CD437, and 
CD2398  (10  -5 M each).  10- 
12 Ixg of total RNA was ana- 
lyzed on 1% agarose-formal- 
dehyde  gels,  transferred  to 
nylon  membranes,  and  hy- 
bridized  with  32P-labeled 
c-fos, c-]un, and p53 probes. 
The  original  data  from 
Northern blots were digitally 
processed  using  a  Hewlett- 
Packard Scan Jet Ilcx. 
for the  in  vivo situation,  the  human  melanoma cell line 
MeWo was established to grow in nude mice. Preexisting 
tumors of 0.5  cm in diameter were treated for 3 wk with 
CD437  (10  and  30  mg/kg)  in  comparison  to  a  vehicle- 
treated  group  of  control  animals.  Tumors  in  CD437- 
treated mice stopped growing, an effect that  became al- 
ready statistically significant (P <  0.01) at day 13, 3 d after 
first  administration  of  CD437,  and  was  maintained  for 
more than 3 wk after discontinuation of treatment. No dif- 
ference was observed depending on the route of adminis- 
tration (intratumorally or orally) (Fig. 8). Intratumoral ret- 
inoid injections were chosen as one treatment arm, since 
no  pharmacologic information  regarding  gastrointestinal 
resorption of CD437 upon oral application were available. 
Further  histologic  analysis  demonstrated  marked  c-fos 
mRNA levels at the tumor-stroma edge in CD437-treated 
tumors, as shown by in situ hybridization (Fig. 9 E). TdT- 
mediated deoxyuridine triphosphate-digoxigenin nick end 
labeling  (TUNEL) staining,  a  procedure  that  labels free 
DNA terminal regions and is considered to be an indicator 
of cells undergoing apoptosis in situ (Fig. 9 D), showed a 
staining pattern that colocalized to the area of high c-los 
expression in the CD437-treated tumors (Fig. 9 E). Analy- 
sis  of saline-treated  control  xenografts demonstrated  no 
comparable c-fos expression or TUNEL staining (not shown). 
Discussion 
In the present study, we have identified the synthetic reti- 
noid CD437 as being able to rapidly induce increased AP-1 
DNA-binding  resulting  in  an  upregulation  of  the  tran- 
scriptional activity of AP-1 and the induction of apoptotic 
cell death  in  human  melanoma cells. The observed anti- 
proliferative effect of CD437 is in agreement with the find- 
ings of others that RA and several synthetic retinoids may 
function as inductors of apoptosis in various cell lines (Alles 
and  Sulik,  1990;  Piacentini  et al.,  1991;  Horie  and  Brox- 
meyer, 1995; Shao et al., 1995).  Antiproliferative effects of 
retinoids are presently believed to be mediated by an inhi- 
bition of AP-1  activity as a  result of the competition for 
DNA-binding  sites  and  of  protein-protein  interactions 
(Sch01e et at., 1990,  1991; Yang-Yen et al., 1991;  Auwerx 
and Sassone-Corsi, 1992;  Pfahl, 1993;  Fanjul et al., 1994; 
J.-Y. Chen et al., 1995; Li et al., 1996). The present report 
describes for the first time a retinoid-induced programmed 
cell death that is accompanied by an activation and upreg- 
ulation of AP-1. It remains to be shown whether other syn- 
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Figure 8.  Growth kinetics of MeWo melanoma cells xenografted 
onto nude mice treated with CD437 or saline. Mice with preexist- 
ing MeWo tumors (groups of eight mice each) were fed for 3 wk 
with various concentrations  of CD437 (10 and 30 mg/kg) or sa- 
line. In addition,  one group was injected with CD437 (10 mg/kg) 
or saline directly  into the tumor (i.t.)  each day. Tumor volume 
differences were statistically significant (P < 0.01) starting at day 13. 
Schadendorf et al. Retinoid-induced Programmed Cell Death of Melanoma  1895 Figure 9.  Evaluation of melanoma xenograft treated with CD437 (10 mg/kg body weight) at day 28. (A) H&E stain of CD437-treated 
cutaneous tumor (125 x). (B-F) Higher magnification (500×). (B) H&E stain of the rectangular area marked in A. (C) In situ hybridiza- 
tion of 13-actin to control RNA integrity. (D) TUNEL staining of CD437-treated melanoma using the ApopTag in situ apoptosis detec- 
tion kit (Oncor Inc., Gaithersburg, MD). (E) In situ hybridization of c-fos in antisense. (F) In situ hybridization of c-los in sense orienta- 
tion. Bar: (A) 0.3 mm; (B-F) 10 ~m. 
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thus a new class of retinoids. 
Evidence for the occurrence of apoptotic cell death in 
human melanoma cells is provided by the demonstration 
of  DNA  fragmentation  and  by  electron  microscopical 
analysis of cell morphology. Only very recently, Shao and 
coworkers have shown that CD437 also induces apoptotic 
cell death in human breast cancer cells (Shao et al., 1995). 
The present study provides additional data regarding the 
molecular mechanisms involved in this process. Thus, mel- 
anoma cell death upon treatment with CD437 in vitro was 
preceded by a substantial upregulation of the AP-1 com- 
plex  (3  h  after  exposure)  as  demonstrated  by  electro- 
phoretic mobility shift assays  (Fig. 6).  Neither unrelated 
transcription factors such as Oct-1 or Nil-2 nor changes in 
the  expression  of p53  or  bcl-2,  which  encode  proteins 
known for their critical involvement in regulating apop- 
totic processes in various cell types, were modulated by 
CD437,  suggesting  that  cell  death  was  independent  of 
these factors and that AP-1 activation upon CD437 treat- 
ment is a specific event. The data presented show that AP-1 
activity is regulated at both a posttranslational and tran- 
scriptional level. Although it is  not known which of the 
posttranslational  mechanisms  described  (for  review  see 
Piechaczyk and Blanchard, 1994)  are involved in upregu- 
lating AP-1 activity, modification of Fos and/or Jun pro- 
tein activity seems  to be  an  early event during  CD437- 
induced  programmed  cell  death.  In  contrast,  transcrip- 
tional activation of the corresponding genes could be de- 
tected  by  Northern  blot  analysis  only  after  prolonged 
treatment with CD437 (24-48 h). 
An increase of c-los and c-jun expression preceding pro- 
grammed cell death has been described in diverse systems 
such as growth factor deprivation of lymphoid cells (Co- 
lotta et  al.,  1992),  hormonal  deprivation  of rat  prostate 
cells  (Buttyan  et  al.,  1988),  involution  of the  lactating 
mammary gland (Marti et al., 1994), or the massive upreg- 
ulation of the AP-1 complex in UV-damaged cells under- 
going  apoptosis  (Devary  et  al.,  1991;  Engelberg  et  al., 
1994; Schreiber et al., 1995). Furthermore, neuronal apop- 
tosis,  which  has  recently been  examined in  great  detail 
(Smeyne et al.,  1993; Estus et al., 1994; S.C. Chen et al., 
1995), is characterized by a  well-defined change  in pro- 
tooncogene expression with an increase of c-los and c-]un 
expression, whereas  expression of other genes encoding 
AP-1 components such as fra-1 are downregulated (Estus 
et al.,  1994). At present, it seems safe to conclude from 
studies in transgenic mice that neuronal death as well as 
programmed cell death in other mesenchymal tissues such 
as chondrocytes and bone is preceded by a continuous c-los 
expression (Smeyne et al.,  1993;  Estus et al.,  1994;  S.C. 
Chen et al.,  1995).  Since melanoma cells are also derived 
from neuroectoderm, it is reasonable to suggest that the 
cascade of gene expression leading to apoptotic cell death 
might be similar. Presently, it is not entirely clear whether the 
whole cascade known to occur during neuronal cell death 
also takes place during CD437-induced melanoma cell death. 
In CD437-treated ceils studied here, c-Fos, c-Jun, and 
JunD  are involved in AP-1 complex formation as shown 
by band shift analysis (Fig. 6 D). In contrast, in cells ex- 
posed to RA,  c-Jun, JunD,  and Fra-1  were found to be 
part of AP-1, whereas c-Fos is missing. It is well known 
that by heterodimerization of Fos (c-Fos, FosB, and Fra-1) 
and  Jun  (c-Jun,  JunB,  and  JunD)  proteins  and  homo- 
dimerization  of Jun  proteins,  >20  different AP-1  com- 
plexes can be formed. Studies with neuronal cells revealed 
that these complexes represent at least four groups with 
transactivational abilities ranging from high to very low (for 
review see Hughes and Dragunow, 1995). c-Fos/c-Jun het- 
erodimers  belong  to  the  group  exhibiting  the  highest 
DNA-binding and transactivational potential, whereas AP-1 
complexes built  up  by Fra-1  and  different Jun  proteins 
were much less active (Hughes and Dragunow, 1995).  In 
agreement with these  earlier studies, we found that  the 
highest AP-l-dependent CAT activity in cells treated with 
CD437  (Fig. 5) was most likely due to the formation of 
c-Fos/c-Jun heterodimers. In contrast, AP-1  constituents 
detected in RA-treated ceils (Fig. 6 D) only allow forma- 
tion of AP-1 complexes with medium to very low activity 
(Hughes and Dragunow, 1995). The finding that treatment 
of MeWo  cells  with  different retinoids  induces  distinct 
AP-1 complexes is supported by our results of Northern 
blot analysis (Fig. 7). Induction of c-fos mRNA could only 
be detected in CD437-treated cells. 
While the components of the cellular signal transduction 
cascade  responsible  for  the  induction  of  apoptosis  are 
presently unknown, it is very likely that alterations in gene 
expression resulting from changes in the composition of 
AP-1 are instrumental. Novel biochemical evidence indi- 
cates that the composition of AP-1 complexes and addi- 
tional  interacting proteins may predict subsequent  gene 
expression and facilitate the switching between prolifera- 
tion, terminal differentiation, and apoptosis (S.C. Chen 
et al., 1995; Hagmeyer et al., 1995; Schreiber et al.,  1995; 
Kamei et al., 1996). 
Taken together, our data suggest that apoptosis in hu- 
man melanoma cells may be similar to neuronal cell death 
and programmed cell death in other mesenchymal tissues, 
with an upregulation of c-los and c-jun expression preced- 
ing cell death. Furthermore, we describe CD437 as a mem- 
ber of a possible new class of synthetic retinoids that is 
capable of initiating the cell death program in human mel- 
anoma cells in vitro and that inhibits growth of xenografts 
in nude mice. Pharmacological induction of apoptosis in 
neoplastic cells is an aim of cancer therapy (Martin and 
Green, 1994). Consequently, CD437 might be the first syn- 
thetic retinoid of a new generation of therapeutic agents 
inducing apoptosis via AP-1  activation and might there- 
fore open up new opportunities for the treatment of meta- 
static melanoma. 
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